|
Recent Developments |
|
30-JUL-18
Morepen Laboratories has received US FDA (United States Food and Drug Administration) approvals for both its bulk drugs manufacturing facilities situated in Himachal Pradesh. While the Baddi facility has got US FDA approval for the manufacture of bulk drug
21-DEC-17
Morepen Laboratories has received approval from United States Food and Drug Administration (USFDA) for Montelukast Sodium, a bulk drug/ API to sell in the US market.
11... More.. |
| Business Profile |
Future Plans |
|
|
|
|
One To One
|
|
Recent news
|
|
|
| Period ending (months) | 31-Dec-2018(9) | 31-Mar-2018 (12) | 31-Mar-2017 (12) | | Net sales | 3604.34 | 5608.30 | 5370.35 | | Other Income | 26.44 | 35.40 | 36.95 | | Total Income | 3630.78 | 5643.70 | 5407.30 | | Cost of goods sold | -3461.60 | 5048.55 | 5176.89 | | OPBDIT | 7092.38 | 595.15 | 230.41 | | PAT | 194.92 | 261.15 | 230.42 | | Gross Block | - | - | - | | Equity capital | - | 0.00 | 0.00 | | EPS (Rs.) | - | 0.00 | 0.00 | | DPS (Rs.) | - | - | - | | BV (Rs.) | - | - | - | | P/E range (x) | - | NA | NA | | Debt / Equity (x) | - | - | - | | Operating margin (% of OI) | 195.3 | 10.5 | 4.3 | | Net margin (% of OI) | 5.4 | 4.6 | 4.3 |
|
|
Detailed Financials
|
|
|
|
|
